InsidersTradesSigma
Follow the Axsome Therapeutics, Inc. stock price and the full management transaction log of the company, a listed issuer based in United States. Shares trade on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Axsome Therapeutics, Inc. has logged 99 public disclosures. Market capitalisation: €10.4bn. The latest transaction was reported on 3 September 2026 (Levée d'options). Among the most active insiders: Coleman Mark. The full history is openly available.
99
Insider Decl.
n/a
Thresholds
€444,720
8 ops.
Buy Volume
€42m
33 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Axsome Therapeutics, Inc. Strong Buy (bullish), based on 21 analysts. Average price target: US$285.42.
38Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 22,593 of 29,063 companies
32.4
score / 100
Value31
Quality34
FCF yld-0.9%
Earn yld-1.8%
EV/EBITDA·
ROE-245%
Gross mgn93%
Net mgn-29%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 3 September 2026
Declarations99 total
10,000 shares@ US$12.950.0012% mcap1.1% of flowCommon StockSEC:0001193125-26-382277:0
10,000 shares@ US$208.650.020% mcap17.4% of flowCommon StockSEC:0001193125-26-382277:1
10,000 shares@ US$208.35Class A CommonSEC144:0001958244-26-000571
45,004 shares@ US$4.950.0020% mcap1.1% of flowCommon StockSEC:0001193125-26-340688:0
45,004 shares@ US$212.010.087% mcap46.2% of flowCommon StockSEC:0001193125-26-340688:1
4,660 shares@ US$4.950.0002% mcap0.1% of flowCommon StockSEC:0001193125-26-340688:2
4,660 shares@ US$213.950.0091% mcap4.8% of flowCommon StockSEC:0001193125-26-340688:3
4,660 shares@ US$210.130.0089% mcap2.8% of flowCommon StockSEC144:0001958244-26-000491
45,004 shares@ US$212.850.088% mcap28.3% of flowCommon StockSEC144:0001958244-26-000488
49,666 shares@ US$240.660.094% mcap100.0% of flowCommon StockSEC144:0001958244-26-000417
49,666 sharesCommon StockSEC:0001193125-26-292985:0
49,666 sharesCommon StockSEC:0001193125-26-292985:1
286 shares@ US$249.11890.0006% mcap0.8% of flowCommonSEC144:0001921094-26-000636
286 sharesCommon StockSEC:0001193125-26-268202:0
286 sharesCommon StockSEC:0001193125-26-268202:1
643 shares@ US$249.00310.0013% mcap1.5% of flowCommonSEC144:0001921094-26-000631
286 shares@ US$246.17830.0006% mcap0.8% of flowCommonSEC144:0001921094-26-000632
300 shares@ US$246.180.0006% mcap50.9% of flowCommonSEC144:0001921094-26-000633
1,429 sharesCommon StockSEC:0001193125-26-266433:0
643 sharesCommon StockSEC:0001193125-26-266433:1
1,429 sharesCommon StockSEC:0001193125-26-266435:0
300 sharesCommon StockSEC:0001193125-26-266435:1
300 sharesCommon StockSEC:0001193125-26-266435:2
1,429 sharesCommon StockSEC:0001193125-26-266436:0
1,429 sharesCommon StockSEC:0001193125-26-266437:0
25 of 99 declarations
关于 Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. 是一家总部位于美国的生物制药公司，专注于中枢神经系统 (CNS) 疾病。由于持续未满足的医疗需求，该治疗领域既具有临床挑战性，又具有商业吸引力。Axsome 成立于 2012 年，其战略围绕开发和商业化针对精神和神经疾病的差异化疗法。该公司在纳斯达克上市，股票代码为 AXSM，公司总部位于美国纽约。([stockanalysis.com](https://stockanalysis.com/stocks/axsm/company/?utm_source=openai)) Axsome 的商业模式现在将已上市产品与处于后期阶段的 CNS 产品线相结合。其核心商业资产包括获批用于成人重度抑郁症的 AUVELITY；用于治疗与发作性睡病或阻塞性睡眠呼吸暂停相关的过度嗜睡的 SUNOSI；以及 SYMBRAVO，该产品于 2025 年 1 月获得 FDA 批准，用于成人有或无先兆偏头痛的急性治疗。该公司还强调其用于特定配方的专有 MoSEIC 技术，并将其产品组合定位为旨在解决复杂 CNS 症状的多机制方法。([stockanalysis.com](https://stockanalysis.com/stocks/axsm/company/?utm_source=openai)) 从竞争角度来看，Axsome 在竞争激烈的市场中运营，这些市场由大型制药公司以及专注于神经科学的专业公司主导。其差异化在于产品创新、临床执行以及其已上市产品组合的逐步扩张。Axsome 将自己描述为针对现有选择有限的疾病中的治疗空白，如果医生采纳率和支付方可及性持续改善，这可以支持其高端定位。([axsome.com](https://www.axsome.com/about-axsome/)) 从地理上看，该公司主要以美国为中心。其商业足迹、收入产生和主要的监管互动主要与美国相关，尽管一些 SEC 文件提及与非美国权利或结构相关的实体和协议。对于投资者而言，实际运营基础仍然绝大多数在美国。([sec.gov](https://www.sec.gov/Archives/edgar/data/1579428/000095017025058788/axsm_fy2024_ars.pdf)) 近期发展对投资案例很重要。2025 年 1 月，FDA 批准了 SYMBRAVO，Axsome 表示正在准备于 2025 年 6 月开始商业发布。该公司还在阿尔茨海默病激越的 AXS-05 方面取得了进展，包括在 2025 年 3 月与 FDA 进行了积极的 NDA 前互动，并计划提交补充 NDA。与此同时，Axsome 继续扩大其销售团队并加强围绕 AUVELITY 和 SUNOSI 的商业基础设施。总而言之，这些里程碑巩固了 Axsome 作为一家纳斯达克上市的美国神经科学成长型公司的形象，该公司正在从以开发为主的执行向更加多元化的商业平台转型。([axsometherapeuticsinc.gcs-web.com](https://axsometherapeuticsinc.gcs-web.com/node/12031/pdf))
